44 research outputs found
Primary immune thrombocytopenia: Experience of a specialised clinic
Introduction: Although primary immune thrombocytopenia (ITP) is rare in childhood, it is the most frequent cause of thrombocytopenia. There have been attempts to establish risk factors to predict the progression of the disease in order to optimise its management, which has changed in recent years due to, among other reasons, specialised care.
Material and methods: A retrospective, observational and analytical study was conducted on patients diagnosed with ITP over a 3-year period in a Paediatric Haematology specialist clinic.
Results: From the epidemiological, clinical and analytical point of view, the characteristics of this group are similar to others. Most of the patients (23/31, 74.2%) had ITP for less than 12 months, with there being no serious complications related to the disease or the treatment received. It was established that risk factors were related to being slowly evolving (lower event free survival (EFS)) with no statistical significance, female gender, age over 10 years, leukopenia absence of initial severe thrombocytopenia, and non-specialised care. The absence of a history of infection was significantly related to a lower EFS.
Conclusions: The epidemiological and analytical risk factors for a slowly evolving ITP are the same that described in the literature. Patients treated before the beginning of specialised care also had a lower EFS. These data seem to support the current recommendation that rare diseases should be managed in specialised units. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Asociaci6n Espanola de Pediatria. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
EvoluciĂłn del riesgo cardiometabĂłlico en pacientes supervivientes de leucemia aguda infantil
IntroducciĂłn: los supervivientes de leucemia aguda (LA) infantil presentan un riesgo incrementado de alteraciones metabĂłlicas y cardiovasculares que aumentan su morbimortalidad a largo plazo.Objetivo: estimar la prevalencia de obesidad, resistencia a la insulina, dislipemia e hipertensiĂłn arterial como factores de riesgo cardiometabĂłlico (FRCM) en un grupo de supervivientes de LA infantil, y analizar las posibles causas asociadas a su desarrollo.Material y mĂ©todos: estudio observacional retrospectivo en 47 supervivientes de LA tratados en un periodo de 4 años, que recibieron seguimiento durante 10 años.Resultados: el 40% de los participantes presentaron al menos un FRCM durante el seguimiento, siendo la dislipemia (aumento LDL) el mĂĄs frecuente (38, 3%), seguido de obesidad/sobrepeso (31, 9%) y HTA sistĂłlica (23, 4%). El sexo femenino se estableciĂł como factor de riesgo parael desarrollo de todos ellos (RR 1, 6; RR 3, 16; RR 1, 69; p < 0, 05). NingĂșn superviviente desarrollĂł diabetes mellitus, pero sĂ resistencia a la insulina el 19, 4%. Los pacientes con leucemias de peor pronĂłstico presentaron mayor riesgo de desarrollar obesidad, resistencia a la insulina y aumento de LDL (RR 3, 56; RR 4, 08; RR 2, 53; p < 0, 05). Los pacientes tratados con trasplante de progenitores hematopoyĂ©ticos presentaron mayor riesgo de obesidad, aumento de LDL e HTA sistĂłlica (RR 2, 86; RR 2, 39; RR 3, 12; p<0, 05). La radioterapia se asociĂł de igual modo con un incremento de resistencia a la insulina e hipertensiĂłn arterial sistĂłlica (RR 2, 47; RR 2, 53; p < 0, 05).Conclusiones: existe un aumento en la prevalencia de obesidad/sobrepeso, dislipemia, resistencia a la insulina y alteraciĂłn de la tensiĂłn arterial sistĂłlica en supervivientes de leucemia aguda infantil a lo largo del tiempo, especialmente en aquellos con enfermedades y tratamientos mĂĄs agresivos.
Background: Survivors of childhood acute leukemia (AL) face an increased risk of metabolic and cardiovascular late effects which increase their long-term morbimotality. Objective: To assess the prevalence of obesity, insulinresistance, dyslipidemia and hypertension as cardiometabolic risk factors in survivors of a childhood AL, and also to determine possible causes for these adverse cardiometabolic traits. Material and methods: A retrospective cohort study of 47 pediatric acute leukemia survivors diagnosed between 0-15 years, with a ten years follow-up. Results: Forty percent of participants had at least one cardiometabolic risk factor. Dyslipidemia (increased LDL cholesterol) was the most frequent (38.3%), secondly overweight/obese (31.9%), followed by systolic hypertension (23.4%). Females in contrast to males had an increased risk of developing all three risk factors (RR 1.6; RR 3.16; RR 1.69; p < 0.05). Only 19.4% of participants developed insulin resistance, while none were diagnosed with diabetes mellitus. High risk acute leukemia survivors were significantly more likely than low risk leukemia survivors to manifest multiple cardiometabolic traits like overweight/obesity, insulin resitance and dyslipidemia (RR 3.56; RR 2.39; RR 2.53; p < 0.05). Also, those who received hematopoietic cell trasplantation had an increased prevalence of overweight/obesity, increased LDL-cholesterol and systolic hypertension. Radiotherapy treatment was also associated with insulin resitance and systolic hypertension (RR 2.47; RR 2.53; p < 0.05). Conclusions: There is an increased risk of overweight/obesity, dyslipidemia, insulin resistance and systolic blood pressure modification in childhood acute leukemia survivors, specially in those who were diagnosed as a high risk acute leukemia and those treated with more aggressive treatments
Trombocitopenia inmune primaria: experiencia de una consulta especializada
IntroducciĂłn
La trombocitopenia inmune primaria (PTI) es poco frecuente en la infancia, pero es la causa mĂĄs habitual de trombocitopenia. Se han intentado establecer factores de riesgo para predecir su evoluciĂłn, con el objetivo de poder optimizar su manejo, que se ha modificado en los Ășltimos años, debido, entre otros factores, a una atenciĂłn mĂĄs especializada.
Material y métodos
Estudio retrospectivo, observacional y analĂtico de los pacientes con PTI, en un periodo de 3 años, en una consulta especializada en HematologĂa PediĂĄtrica.
Resultados
Desde el punto de vista epidemiolĂłgico, clĂnico y analĂtico, las caracterĂsticas de esta serie son similares a las de otros grupos. La mayorĂa de los pacientes (23/31; 74,2%) presentaron una PTI de duraciĂłn menor de 12 meses, sin complicaciones graves relacionadas con la enfermedad ni con el tratamiento. Se establecieron como factores de riesgo relacionados con una evoluciĂłn tĂłrpida (supervivencia libre de eventos [SLE] menor), sin alcanzar la significaciĂłn estadĂstica, el sexo femenino, la edad mayor de 10 años, la leucopenia, la ausencia de trombocitopenia grave inicial y la atenciĂłn no especializada. La ausencia de antecedente de infecciĂłn se relacionĂł significativamente con una SLE menor.
Conclusiones
Los factores de riesgo de evoluciĂłn tĂłrpida de PTI epidemiolĂłgicos y analĂticos de este estudio coinciden con los descritos en la literatura. Presentaron una SLE menor los pacientes tratados antes del inicio de la atenciĂłn especializada. Estos datos parecen apoyar la recomendaciĂłn actual de que las enfermedades poco frecuentes, como esta, se controlen en unidades especializadas
Hypogonadotropic hypogonadism in Klinefelter syndrome and hypothalamic-pituitary tumor
El sĂndrome de Klinefelter es la causa mĂĄs frecuente de hipogonadismo hipergonadotropo en el varĂłn. La supresiĂłn en la respuesta al estĂmulo con hormona liberadora de la hormona luteinizante en estos pacientes debe hacer sospechar como posible etiologĂa una tumoraciĂłn a nivel hipotalĂĄmico. Se presenta el caso de un paciente diagnosticado a los 4 meses con sĂndrome de Klinefelter mediante cribado neonatal, con cariotipo 47 XXY, en el que se realizan controles clĂnicos y analĂticos seriados y se encuentran, a los 17 años, valores suprimidos de hormona luteinizante y hormona folĂculo estimulante. Inicia, posteriormente, cefalea y amaurosis de ojo izquierdo, y se encuentra, en una resonancia magnĂ©tica cerebral, un tumor germinal mixto a nivel hipotalĂĄmico, que precisa tratamiento quirĂșrgico, quimioterapia y radioterapia, con respuesta favorable.
Klinefelter Syndrome is the most frequent cause of hypergonadotropic hypogonadism in men. A flat response at luteinizing hormone releasing hormone stimulation test could be the first sign of hypothalamic tumor in these patients. We report the case of a patient diagnosed by neonatal screening with Klinefelter Syndrome, 47 XXY, that at 17 years follow-up presents analytical modification of the response to luteinizing hormone releasing hormone stimulation test with suppressed luteinizing hormone and follicle-stimulating hormone values; lately he presents with headache and loss of left eye vision. A magnetic resonance imaging of the brain showed a mixed germ cell hypothalamus tumor, requiring surgery, chemotherapy and radiotherapy with optimal response
RICORS2040 : The need for collaborative research in chronic kidney disease
Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Background:
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.
Methods:
We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30â50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515.
Findings:
Patients were screened between July 1, 2015, and Nov 24, 2016. 10â793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68â0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group.
Interpretation:
In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.
Funding:
GlaxoSmithKline
Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells
Brca1- and Brca2-deficient cells have reduced capacity to repair DNA double-strand breaks (DSBs) by homologous recombination (HR) and consequently are hypersensitive to DNA damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors. Here we show that loss of the MLL3/4 complex protein, PTIP, protects Brca1/2-deficient cells from DNA damage and rescues the lethality of Brca2-deficient embryonic stem cells. However, PTIP deficiency does not restore HR activity at DSBs. Instead, its absence inhibits the recruitment of the MRE11 nuclease to stalled replication forks, which in turn protects nascent DNA strands from extensive degradation. More generally, acquisition of PARPi and cisplatin resistance is associated with replication fork (RF) protection in Brca2-deficient tumor cells that do not develop Brca2 reversion mutations. Disruption of multiple proteins, including PARP1 and CHD4, leads to the same end point of RF protection, highlighting the complexities by which tumor cells evade chemotherapeutic interventions and acquire drug resistance
Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status
Study of eta-eta ' mixing from measurement of B-(s)(0) -> J/psi eta((')) decay rates
A study of B and Bs meson decays into J/Ï Î· and J/Ï Î·âČ final states is performed using a data set of proton-proton collisions at centre-of-mass energies of 7 and 8 TeV, collected by the LCHb experiment and corresponding to 3.0 fbâ1 of integrated luminosity. The decay B0 â J/Ï Î·âČ is observed for the first time. The following ratios of branching fractions are measured:
B(B0âJ/ÏηâČ)B(B0sâ J/ÏηâČ)=(2.28±0.65 (stat)±0.10 (syst)±0.13 (fs/fd))Ă10â2,B(B0â J/Ïη)B(B0sâ J/Ïη)=(1.85±0.61 (stat)±0.09 (syst)±0.11 (fs/fd))Ă10â2, where the third uncertainty is related to the present knowledge of fs/fd, the ratio between the probabilities for a b quark to form a Bs or a B0 meson. The branching fraction ratios are used to determine the parameters of η â ηâČ meson mixing. In addition, the first evidence for the decay Bs â Ï(2S)ηâČ is reported, and the relative branching fraction is measured,
B(B0sâ Ï(2S)ηâČ)B(B0sâ J/ÏηâČ)=(38.7±9.0 (stat)±1.3 (syst)±0.9(B))Ă10â2, where the third uncertainty is due to the limited knowledge of the branching fractions of J/Ï and Ï(2S) mesons